David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
Elbit Systems
ESLT
$33.8B
| $321K | ﹤0.01% |
+2,487
| New | +$317K |
|
3152
Ituran Location and Control
ITRN
$1.01B
| $319K | ﹤0.01% |
+9,348
| New | +$319K |
|
|
DRE
3153
DELISTED
Duke Realty Corp.
DRE
| $317K | ﹤0.01% |
10,381
-465,468
| -98% | -$13.6M |
|
|
TRK
3154
DELISTED
Speedway Motorsports, Inc.
TRK
| $317K | ﹤0.01% |
21,879
-6,128
| -22% | -$101K |
|
3155
Assurant
AIZ
$14.1B
| $316K | ﹤0.01% |
+3,326
| New | +$322K |
|
|
CHK
3156
DELISTED
Chesapeake Energy Corporation
CHK
| $316K | ﹤0.01% |
509
-5,895
| -92% | -$3.3M |
|
3157
Fidus Investment
FDUS
$750M
| $314K | ﹤0.01% |
20,508
-20,165
| -50% | -$290K |
|
3158
Nabors Industries
NBR
$1.3B
| $314K | ﹤0.01% |
1,823
+569
| +45% | +$88.5K |
|
3159
Waterstone Financial
WSBF
$378M
| $314K | ﹤0.01% |
19,088
-14,538
| -43% | -$241K |
|
3160
PUT
Nucor
NUE
$56.2B
| $309K | ﹤0.01% |
5,300
-4,500
| -46% | -$264K |
|
|
CLVS
3161
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $308K | ﹤0.01% |
12,400
-15,200
| -55% | -$381K |
|
|
DX
3162
Dynex Capital
DX
$3.23B
| $305K | ﹤0.01% |
16,699
+12,598
| +307% | +$230K |
|
3163
PUT
Hain Celestial
HAIN
$78.9M
| $305K | ﹤0.01% |
+13,200
| New | +$254K |
|
3164
Matador Resources
MTDR
$6.87B
| $305K | ﹤0.01% |
15,778
-236,786
| -94% | -$4.41M |
|
3165
Spire
SR
$4.92B
| $305K | ﹤0.01% |
3,704
-12,777
| -78% | -$996K |
|
3166
PUT
Polaris
PII
$3.62B
| $304K | ﹤0.01% |
3,600
-47,100
| -93% | -$4M |
|
3167
SouthState Bank Corp
SSB
$10.3B
| $304K | ﹤0.01% |
4,454
-925
| -17% | -$62.1K |
|
3168
Kimco Realty
KIM
$16.1B
| $303K | ﹤0.01% |
16,397
-3,143
| -16% | -$53.9K |
|
3169
NBT Bancorp
NBTB
$2.67B
| $303K | ﹤0.01% |
8,413
+2,242
| +36% | +$82.7K |
|
|
FISV
3170
Fiserv Inc
FISV
$27.9B
| $300K | ﹤0.01% |
+3,398
| New | +$280K |
|
|
BHBK
3171
DELISTED
Blue Hills Bancorp, Inc.
BHBK
| $300K | ﹤0.01% |
12,547
-30,238
| -71% | -$710K |
|
|
CTLP
3172
DELISTED
Cantaloupe
CTLP
| $299K | ﹤0.01% |
+72,126
| New | +$323K |
|
3173
PUT
Jabil
JBL
$32.3B
| $298K | ﹤0.01% |
11,200
-103,500
| -90% | -$2.76M |
|
|
TREC
3174
DELISTED
Trecora Resources
TREC
| $298K | ﹤0.01% |
32,749
+4,376
| +15% | +$39K |
|
3175
DXP Enterprises
DXPE
$2.92B
| $297K | ﹤0.01% |
7,639
-1,948
| -20% | -$67.8K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.